<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Interventions</th>
<th>Outcomes</th>
<th>Analgesic results</th>
<th>Adverse events, withdrawals &amp; exclusions</th>
<th>Quality score</th>
</tr>
</thead>
</table>
| Brown et al, 1997  | Randomised, double blind, placebo and active controlled trial in major abdominal or orthopaedic surgery. 12 hour study on day one. | 5 parallel groups: naproxen Na 550 mg, n=46 placebo, n=43 bromfenac 25 mg, n=44 bromfenac 50 mg, n=43 IM ketorolac 30 mg, n=30 | Standard 4 point pain intensity & 5 point pain relief scales and non-standard 5 point global scale. Pain assessed at 0.25, 0.5 hrs, then hourly up to 12 hours by patient | At least 50% pain relief: naproxen Na 550 mg 16/46 6 hr TOTPAR: naproxen Na = 7.48 placebo = 3.91 | Patients reporting any adverse event: naproxen Na = 7/46 placebo = 8/43 1 withdrawal in naproxen Na group due to oral medication intolerance | R =1  
DB = 2  
W = 1  
Total = 4 |
| Forbes et al, 1986 | Randomised, double blind, placebo and active controlled trial in dental surgery. 12 hour study. | 5 parallel groups: naproxen Na 550 mg, n=38 placebo, n=42 codeine sulfate 60 mg, n=44 naproxen Na 550 mg & codeine 60 mg, n=38 aspirin 650 mg, n=36 | Standard 4 point pain intensity & 5 point pain relief scales and standard 5 point global scale. Pain assessed at hourly intervals up to 12 hrs by patient | At least 50% pain relief: placebo 5/42 naproxen Na 550 mg 22/38 6 hr TOTPAR: naproxen Na = 12.76 placebo = 4.07 6hr SPID: naproxen Na = 7.13 placebo = 1.31 Median time to remedicaton: placebo = 5.3 hrs naproxen Na = 8.3 hrs Remedicaton by 12 hrs: placebo = 81% naproxen Na = 60% | Patients reporting any adverse event: naproxen Na = 7/38 placebo = 7/42 46 patients did not take study medication. 24 had invalid efficacy data. | R =2  
DB = 2  
W = 1  
Total = 5 |
| Gottesdiener et al, 1999 | Randomised, double blind, placebo and active controlled trial in dental surgery. 24 hour study. | 5 parallel groups: naproxen Na 550 mg, n=25 placebo, n=25 DFP 5 mg, n=48 DFP 25 mg, n=50 DFP 50 mg, n=48 | Standard 4 point pain intensity & 5 point pain relief scales and standard 5 point global scale. Pain assessed at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 hrs then hourly up to 12 hrs by patient | At least 50% pain relief: placebo 2/25 naproxen Na 550 mg 15/25 6 hr TOTPAR: placebo = 3.40 naproxen Na = 13.0 6 hr SPID: placebo = -0.98 naproxen Na = 6.45 Median time to remedicaton: placebo = 1.6 hrs naproxen Na = 8.0 hrs Remedicaton by 24 hrs: placebo = 92% naproxen Na = 60% | Patients reporting any adverse event: naproxen Na = 6/25 placebo = 12/25 No exclusions. | R =1  
DB = 2  
W = 1  
Total = 4 |
| Reicin et al, 2001  | Randomised, double blind, placebo and active controlled trial in major orthopaedic surgery. 12 hour study on day one. | 4 parallel groups: naproxen Na 550 mg, n=55 placebo, n=53 rofecoxib 50/25 mg, n=56 rofecoxib 50/50 mg, n=54 | Standard 4 point pain intensity & 5 point pain relief scales and standard 5 point global scale. Pain assessed at 0.5, 1.0, 1.5, 2.0 hrs, then hourly up to 12 hours by patient | At least 50% pain relief: Placebo 10/53 naproxen Na 550 mg 24/55 6 hr TOTPAR: placebo = 5.4 naproxen Na = 9.8 Median time to remedicaton: placebo = 2.8 hrs naproxen Na = 5.9 hrs Remedicaton by 12 hrs: placebo = 93% naproxen Na = 69% | On day 1, discontinuation due to adverse event: naproxen Na = 3.6% placebo = 5.7% | R =2  
DB = 1  
W = 1  
Total = 4 |
Unpublished data
(i) Randomised, double blind, placebo and active controlled trial in dental surgery. 24 hour study.

6 parallel groups:
naproxen Na 550 mg, n=39
placebo, n=38
MK-0966 7.5 mg, n=38
MK-0966 25 mg, n=38
MK-0966 50 mg, n=38
MK-0966 100 mg, n=38

Standard 4 point pain intensity & 5 point pain relief scales. Pain assessed up to 24 hours
At least 50% pain relief: placebo 6/38
naproxen Na 550 mg 28/39
6 hr TOTPAR: placebo = 2.59
naproxen Na = 15.04
Median time to remedication: 
naproxen Na = 12 hrs
placebo = 1.6 hrs
Remedication by 12 hours: 
placebo = 57%
naproxen Na = 43%

Patients reporting any adverse events:
naproxen Na = 9
placebo = 12.

R = 1
DB = 2
W = 0
Total = 3

Unpublished data
(ii) Randomised, double blind, placebo and active controlled trial in dental surgery. 24 hour study.

5 parallel groups:
naproxen Na 550 mg, n=49
placebo, n=47
MK-0966 12.5 mg, n=72
MK-0966 25 mg, n=72
MK-0966 50 mg, n=72

Standard 4 point pain intensity & 5 point pain relief scales. Pain assessed up to 24 hours
At least 50% pain relief: placebo 3/47
naproxen Na 550 mg 24/49
6 hr TOTPAR: placebo = 2.59
naproxen Na = 15.04
Median time to remedication: 
naproxen Na = 5.4 hrs
placebo = 1.5 hrs.
Remedication by 12 hours: 
placebo = 76%
naproxen Na = 75%

Patients reporting any adverse event:
naproxen Na = 18
placebo = 13.

R = 1
DB = 2
W = 0
Total = 3

Kiersch et al, 1994
Randomised, double blind, placebo and active controlled trial in dental surgery. 12 hour study.

3 parallel groups:
naproxen Na 440 mg, n=92
placebo, n=45
acetaminophen 1000 mg, n=89

Standard 4 point pain intensity & 5 point pain relief scales and standard 5 point global scale. Pain assessed at 20, 30, 40 and 60 mins, then hourly up to 12 hours by patient
At least 50% pain relief:
placebo 3/45
naproxen Na 440 mg 43/92
6 hr TOTPAR: 
placebo = 3.10
naproxen Na = 10.50
Median time to remedication: naproxen Na = 9.9 hrs
placebo = 2.0 hrs
6 hr SPID: 
naproxen Na = 4.8
placebo = -1.4

Patients reporting any adverse event:
naproxen Na = 31
placebo = 13
4 did not receive study medications (1 in naproxen Na group due to severe vomiting post-surgery, prior to naproxen Na administration).

R = 1
DB = 2
W = 1
Total = 4

Fricke et al, 1993
Randomised, double blind, placebo and active controlled trial in dental surgery. 12 hour study.

3 parallel groups:
naproxen Na 440 mg, n = 81
placebo, n = 39
ibuprofen 400 mg, n = 81

Standard 4 point pain intensity and 5 point pain relief scales and standard 5 point global scale. Pain assessed at 20, 30, 40 and 60 mins, then hourly up to 12 hours by patient
At least 50% pain relief:
placebo 2/39
naproxen Na 440 mg 43/81
6 hr TOTPAR:
naproxen Na = 11.6
placebo = 2.90
6 hr SPID: 
naproxen Na = 4.8
placebo = -1.4

Patients reporting any adverse event:
naproxen Na = 31
placebo = 13
4 did not receive study medications (1 in naproxen Na group due to severe vomiting post-surgery, prior to naproxen Na administration).

R = 1
DB = 1
W = 1
Total = 3

Kiersch et al, 1993
Randomised, double blind, placebo and active controlled trial in dental surgery. 12 hour study.

3 parallel groups:
naproxen Na 220 mg, n=80
placebo, n=42
ibuprofen 200 mg, n=81

Standard 4 point pain intensity & 5 point pain relief scales and standard 5 point global scale. Pain assessed at 20, 30, 40 and 60 mins, then hourly up to 12 hours by patient
At least 50% pain relief:
placebo 2/42
naproxen Na 440 mg 42/80
6 hr TOTPAR: 
naproxen Na = 11.5
placebo = 3.7
Median time to remedication: naproxen Na = 9.4 hrs
placebo = 2.0 hrs

Patients reporting any adverse event:
naproxen Na = 21
placebo = 5
Severe events in 2 patients on placebo and 7 on naproxen Na but not deemed due to study medications.
2 exclusions due to protocol violations. 4 in placebo group and 40 in treatment group

R = 1
DB = 1
W = 1
Total = 3
<table>
<thead>
<tr>
<th>Study</th>
<th>Design Description</th>
<th>Details</th>
<th>Pain Relief</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mahler et al, 1976</td>
<td>Randomised, double blind, placebo and active controlled trial in orthopaedic or general surgery. 6 hour study.</td>
<td>4 parallel groups: in 2 trials at 2 hospitals. Total no. patients: naproxen 200 mg, n=40 naproxen 400 mg, n=37 placebo, n=40 aspirin 600 mg, n=39 aspirin 1200 mg, n=41</td>
<td>At least 50% pain relief: placebo 9/40 naproxen 400 mg 17/37 naproxen 200 mg 12/40 6 hr weighted mean TOTPAR: naproxen 200 mg = 7.4 naproxen 400 mg = 10.3 placebo = 6.2</td>
<td>Single and multiple dose adverse events combined for both hospitals, therefore no extractable data</td>
</tr>
</tbody>
</table>